Literature DB >> 27645111

Statin intolerance - a question of definition.

Engi Abdel-Hady Algharably1,2, Iris Filler1, Stephanie Rosenfeld3, Katja Grabowski1, Reinhold Kreutz1.   

Abstract

INTRODUCTION: Statin therapy is the backbone of pharmacologic therapy for low-density lipoproteins cholesterol lowering and plays a pivotal role in cardiovascular disease prevention. Statin intolerance is understood as the inability to continue using a statin to reduce individual cardiovascular risk sufficiently, due to the development of symptoms or laboratory abnormalities attributable to the initiation or dose escalation of a statin. Muscle symptoms are the most common side effects observed. Areas covered: The main aim of this article is to present a review on published definitions of statin intolerance. In addition, a brief review on clinical aspects and risk factors of statin intolerance is provided and features for a common definition for statin intolerance are suggested. Expert opinion: A definition of statin intolerance by major drug regulatory agencies is not available. In clinical studies, different definitions are chosen and results are not comparable; different medical associations do not agree on one common definition. There is an unmet need to establish a common definition of statin intolerance to ensure an appropriate clinical use of this important drug class. Further work is required to develop a consensus definition on statin intolerance that could have significant positive impact on both research and clinical management.

Entities:  

Keywords:  HMG-CoA reductase inhibitors; PCSK9 inhibitors; hypercholesterolemia; myopathy; statin adverse effects; statin discontinuation

Mesh:

Substances:

Year:  2016        PMID: 27645111     DOI: 10.1080/14740338.2017.1238898

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  3 in total

Review 1.  Management of Statin Intolerance in 2018: Still More Questions Than Answers.

Authors:  Peter P Toth; Angelo Maria Patti; Rosaria Vincenza Giglio; Dragana Nikolic; Giuseppa Castellino; Manfredi Rizzo; Maciej Banach
Journal:  Am J Cardiovasc Drugs       Date:  2018-06       Impact factor: 3.571

2.  Understanding the Patient Perception of Statin Experience: A Qualitative Study.

Authors:  Michal Vrablik; Alberico L Catapano; Olov Wiklund; Yi Qian; Pratik Rane; Alyson Grove; Mona L Martin
Journal:  Adv Ther       Date:  2019-09-03       Impact factor: 3.845

3.  Statin-associated myopathy. Assessment of frequency based on data of all statutory health insurance funds in Germany.

Authors:  Peter Ihle; Franz-Werner Dippel; Ingrid Schubert
Journal:  Pharmacol Res Perspect       Date:  2018-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.